Last month, word spread that a drug was finally shown to slow Alzheimer’s disease, and overnight a 73-year-old Swedish professor made $350 million.
The lucky man, Lars Lannfelt, was not particularly famous. He had done pioneering work on the disease, but it was in the 90s and belonged to a sub-field that, after a litany of failures and one disastrous approval, had fallen from grace.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
